Incorporating Radioligand Therapy in Clinical Practice in the United States for Patients With Prostate Cancer

In 2022, there will be approximately 268  ,490 newly diagnosed PC patients and 34,500 deaths [1]. Advanced PC evolves to metastatic castration-resistant PC (mCRPC) [2,3], a lethal phenotype, which results in prostate cancer-specific mortality [4–14]. The 5-year survival rate for men diagnosed with metastatic PC between 2011 and 2017 wa s 31% [1], indicating that the development of therapies with novel mechanisms of action demonstrating an overall survival benefit and an acceptable safety profile is needed [5].

Source: Cancer Treatment Reviews - February 10, 2023 Category: Cancer & Oncology Authors: Jeremie Calais, Stephen M. Eulau, Linda Gardner, Ralph J. Hauke, Ayse T. Kendi, Neal D. Shore, Song Zhao Source Type: research